09:59 AM EST - Patheon Inc. : announced that Pharmalink AB, a Swedish specialty pharma company, has entered into a contract with Patheon for the manufacturing of Nefecon®, Pharmalink's lead product. Nefecon is being developed as the first on-label medication specifically aimed at addressing the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease. Patheon Inc.
shares T.PTI are trading up $0.05 at $3.80.
